This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study
- Investigator
- Ali Ataya
- Ages
- 18 Years - 75 Years
- Sexes
- All
Clinical trials
-
GB002-3102